BioSpace News Archive

As its standard practice to employ the most advanced training methods available, Inspired Spine hosted a Surgery Observation and Cadaver Lab last week at its Burnsville campus.

Glaucoma is one of the leading causes of vision loss and blindness, affecting over 3 million Americans, blinding over 120,000.

Arcus Biosciences announced that its management team will participate in the following upcoming investor conferences.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced that Dermata will participate in the Gilmartin Group Emerging Growth Company Showcase, being held on August 31, 2022.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”) – a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs – today reported financial results for its second quarter ended June 30, 2022 and provided a corporate update.

Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference.

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that it will present virtually at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31, 2022.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization (CMA) to ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).

IRIS - Intelligent Retinal Imaging Systems, a leader in retinal screening technology, has partnered with HealPros, a technology-enabled healthcare service that works with some of the largest health plans in the nation to change the lives of people with chronic illness.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.